Results 191 to 200 of about 89,305 (304)

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos, Vincent Piguet, Michael Frank Mørup, Leah Davis, Vanessa Taieb, Sandeep Kiri, Victoria Shodimu, Abby Paine, Brian Kirby, Haley B. Naik   +9 more
wiley   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth, Joseph F. Merola, Richard Furie, Kenneth Kalunian, Ronald F. van Vollenhoven, Juanita Romero‐Diaz, Qianyun Li, Weihong Yang, Catherine Barbey   +8 more
wiley   +1 more source

Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review. [PDF]

Cureus
Sikkal A, Ouahmane S, El Otmani H, El Moutawakil B, Rafai MA.   +4 more
europepmc   +1 more source

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos, Evangelos J. Giamarellos‐Bourboulis, Kelsey R. van Straalen, Antonio Martorell, Brian Kirby, Afsaneh Alavi, Koremasa Hayama, Saakshi Khattri, Wayne Gulliver, Christopher J. Sayed, Leah Davis, Robert L. Rolleri, Christina Crater, Ingrid Pansar, Jérémy Lambert, Christos C. Zouboulis   +15 more
wiley   +1 more source

Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V_H1-2-rearranging mouse models. [PDF]

Proc Natl Acad Sci U S A
Batra H, Luo S, Saunders KO, Higgins JS, Jian F, Zhang J, Kibria MG, Jonaid GM, Zhou QJ, Eaton A, Cronin K, Mallory ML, Mattocks M, Edwards RJ, Parks R, Lee EM, Ye AY, Williams AC, Jung G, Mansouri K, Alam SM, Montefiori DC, Tian M, Baric RS, Cao Y, Haynes BF, Chen B, Alt FW.   +27 more
europepmc   +1 more source

Periodontitis and rheumatoid arthritis—Global efforts to untangle two complex diseases

Periodontology 2000, EarlyView.
Abstract Understanding the impact of oral health on rheumatoid arthritis (RA) will inform how best to manage patients with both periodontitis and RA. This review seeks to provide an update on interventional and mechanistic investigations, including a brief summary of European Research programs investigating the link between periodontitis and RA. Recent
Isabel Lopez‐Oliva, Jennifer Malcolm, Shauna Culshaw   +2 more
wiley   +1 more source

QX008N, an Anti-TSLP Monoclonal Antibody: Pharmacokinetics, Tolerability, and Immunogenicity in Healthy Chinese Subjects. [PDF]

Clin Transl Sci
Shen ZW, Jiang Q, Wu KQ, Jin TH, Zhao J, Guo T, Fang M, Chen GL.   +7 more
europepmc   +1 more source

Cases of AQP4‐Antibody‐Positive Neuromyelitis Optica Spectrum Disorder Successfully Discontinuing Steroids With Satralizumab Treatment: Considerations on the Method of Tapering for Steroids After the Introduction of Satralizumab

Clinical and Experimental Neuroimmunology, Volume 17, Issue 2, May 2026.
ABSTRACT Background Satralizumab is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD). However, there are currently no standardized guidelines regarding the method or speed of steroid tapering after its introduction. In 2023, we proposed a method to commence tapering prednisolone at a rate of 1 mg every 4 weeks, starting 8 weeks ...
Kiyotaka Nakamagoe, Mayuko Tanaka, Kota Igari, Tetsu Suzuki, Shinji Saiki   +4 more
wiley   +1 more source

Understanding Biologics in CRSwNP: Related Events and Insights. [PDF]

Curr Allergy Asthma Rep
Izquierdo-Domínguez A, Al-Salloom Z, Viñas M, Mullol J, Alobid I.   +4 more
europepmc   +1 more source

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

American Journal of Hematology, Volume 101, Issue 4, Page 697-709, April 2026.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong, Tamara Wais, Cecilia Varga, Christina Schueller, Sarada Achyutuni, Robert Kralovics   +5 more
wiley   +1 more source